Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection
Sponsor: Gilead Sciences
Listed as NCT04323761, this observational or N/A phase trial focuses on SARS-CoV2 Infection and remains ongoing. Sponsored by Gilead Sciences, it has been updated 13 times since 2026, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Approved For Marketing
-
Sep 2024 — Sep 2025 [monthly]
Approved For Marketing
-
Jul 2024 — Sep 2024 [monthly]
Approved For Marketing
-
Jan 2021 — Jul 2024 [monthly]
Approved For Marketing
-
Dec 2020 — Jan 2021 [monthly]
Approved For Marketing
Status: No Longer Available → Approved For Marketing
▶ Show 8 earlier versions
-
Nov 2020 — Dec 2020 [monthly]
No Longer Available
Status: Available → No Longer Available
-
Oct 2020 — Nov 2020 [monthly]
Available
-
Sep 2020 — Oct 2020 [monthly]
Available
-
Aug 2020 — Sep 2020 [monthly]
Available
-
Jul 2020 — Aug 2020 [monthly]
Available
-
Jun 2020 — Jul 2020 [monthly]
Available
-
May 2020 — Jun 2020 [monthly]
Available
-
Apr 2020 — May 2020 [monthly]
Available
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarau, Switzerland , Albany, United States , Ancona, Italy , Ann Arbor, United States , Astoria, United States , Atlanta, United States , Aurora, United States , Austin, United States , Aventura, United States , Badalona, Spain and 223 more locations